STX-478 May Improve Therapeutic Index Vs Other PI3K Inhibitors in Cancer

Commentary
Video

Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.

STX-478 has demonstrated clinical activity and tolerability among patients with solid tumors, signaling a new generation of drugs that may be capable of preferentially binding to mutated PI3K, according to Alberto J. Montero, MD, MBA, CPHQ.

CancerNetwork® spoke with Montero, clinical director of the Breast Cancer Medical Oncology Program and medical director of the Clinical Trials Unit at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University School of Medicine, about the implications of data from a phase 1 trial (NCT05768139) assessing treatment with STX-478 for patients with advanced solid tumors harboring PI3Kα mutations.

According to Montero, currently available PI3K inhibitors may be limited by a lack of specificity and toxicities associated with blocking wild-type PI3K. Developers designed STX-478 as an allosteric, mutant-selective PI3K inhibitor that selectively targets PI3Ka mutations, potentially reducing wild-type toxicities in the process. Based on the design of STX-478, Montero stated that the investigational agent may offer a better therapeutic index compared with prior PI3K inhibitors.

Montero previously presented data from the phase 1 trial at the 2024 European Society for Medical Oncology Congress (ESMO).

Transcript:

Much like in non–small cell lung cancer—[where] we have mutation-specific inhibitors for EGFR, which is an important target—one of the key take home messages of this trial is that we can rationally design drugs that specifically and preferentially target mutated PI3K to get that activity. It is a commonly mutated gene and a driver mutation in many solid tumors, but we’ve been limited by the lack of specificity and the [adverse] effects when we block the wild-type PI3K. The take-home message is that we have a newer generation of drugs that preferentially bind to the mutated protein. STX-478 has activity and is well-tolerated [with a] much better therapeutic index than what prior drugs that target PI3K have demonstrated.

Reference

Montero AJ, Giordano A, Jhaveri K, et al. First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients. Ann Oncol. 2024;35(suppl 2):S1220.

Recent Videos
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content